Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enveric Biosciences, Inc.ENVB · Entity 8193 | Chief Innovation Officer | June 01, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enveric Biosciences, Inc.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,755 |
Reported balance
After 2026-06-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 25,000 · Balance 27,755 F1: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company. F2: On October 28, 2025, the common stock of the Company began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the "Reverse Stock Split"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.
F2: On October 28, 2025, the common stock of the Company began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the "Reverse Stock Split"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 20:22 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001883966-26-000003 · ownership.xml · nonDerivative · entry 1 Facchini Peter J. · CIK 0001883966 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,755 F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company. F2 · balance_after: On October 28, 2025, the common stock of the Company began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the "Reverse Stock Split"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split. Read SEC document |
| May 08, 2025 Filed May 12, 2025 21:00 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantCommon Stock | 24,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-012678 · form4-05122025_050503.xml · nonDerivative · entry 1 Facchini Peter J. · CIK 0001883966 · CHIEF INNOVATION OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,058 F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company. F2 · balance_after: On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the "Reverse Stock Split"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split. Read SEC document |
| October 09, 2024 Filed Oct 11, 2024 23:08 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-025050 · form4-10112024_111008.xml · nonDerivative · entry 1 Facchini Peter J. · CIK 0001883966 · CHIEF INNOVATION OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,856 F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 21:47 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-005253 · form4-02262024_090248.xml · nonDerivative · entry 1 Facchini Peter J. · CIK 0001883966 · CHIEF INNOVATION OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,856 F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 22:05 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantCommon Stock | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-002802 · ownership.xml · nonDerivative · entry 1 Facchini Peter J. · CIK 0001883966 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,865 F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. The RSUs vest in four equal installments, with the first installment vesting upon the one year anniversary of the date of issuance. Read SEC document |
| October 13, 2021 Filed Jan 25, 2023 21:30 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-002452 · ownership.xml · nonDerivative · entry 2 Facchini Peter J. · CIK 0001883966 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,856 F3 · shares: 50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on September 16, 2022. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $119.00, $130.50 and $143.50, respectively. F2 · balance_after: Includes 10,633 shares previously held through the Facchini 2020 Family Trust, which were distributed to the reporting person and are now owned directly. Read SEC document |
| October 13, 2021 Filed Jan 25, 2023 21:30 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantCommon Stock | 1,021 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-002452 · ownership.xml · nonDerivative · entry 1 Facchini Peter J. · CIK 0001883966 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,356 F1 · shares: The reporting person received the restricted stock units (RSUs) as a one-time signing bonus upon the commencement of the reporting person's employment with the Company. 50% of the RSUs shall vest over 2 years in equal annual installments, with the first tranche to vest on September 16, 2022. 50% of the RSUs shall vest over 2 years in equal annual installments, if the Company's average VWAP exceeds 110% and 120% of $158.925, respectively. F2 · balance_after: Includes 10,633 shares previously held through the Facchini 2020 Family Trust, which were distributed to the reporting person and are now owned directly. Read SEC document |
| September 16, 2021 Filed Oct 15, 2021 23:12 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantCommon Warrants · Derivative | 2,658 | Not disclosed Strike: $2.82 | Not disclosed |
DisclosureSEC source: 0001493152-21-025625 · ownership.xml · derivative · entry 6 Facchini Peter J. · CIK 0001883966 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,658 Underlying: Common Stock · 2,658 shares Expires 2023-09-16 F7 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants. F10 · price: The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 10,000 shares of common stock of MagicMed with an exercise price of $0.75 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants. Read SEC document |
| September 16, 2021 Filed Oct 15, 2021 23:12 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantCommon Warrants · Derivative | 531,602 | Not disclosed Strike: $0.94 | Not disclosed |
DisclosureSEC source: 0001493152-21-025625 · ownership.xml · derivative · entry 5 Facchini Peter J. · CIK 0001883966 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 531,602 Underlying: Common Stock · 531,602 shares Expires 2025-05-26 F7 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants. F9 · price: The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 2,000,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants. F4 · ownership.nature: Held indirectly through the Facchini 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Facchini and his family. Read SEC document |
| September 16, 2021 Filed Oct 15, 2021 23:12 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantCommon Warrants · Derivative | 79,740 | Not disclosed Strike: $0.94 | Not disclosed |
DisclosureSEC source: 0001493152-21-025625 · ownership.xml · derivative · entry 4 Facchini Peter J. · CIK 0001883966 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,740 Underlying: Common Stock · 79,740 shares Expires 2025-05-26 F7 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants. F8 · price: The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 300,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants. Read SEC document |
| September 16, 2021 Filed Oct 15, 2021 23:12 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantStock Options · Derivative | 99,675 | Not disclosed Strike: $1.88 | Not disclosed |
DisclosureSEC source: 0001493152-21-025625 · ownership.xml · derivative · entry 3 Facchini Peter J. · CIK 0001883966 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,675 Underlying: Common Stock · 99,675 shares Expires 2026-04-05 F5 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each outstanding MagicMed stock option was converted into an option to purchase the number of Company shares equal to the Exchange Ratio multiplied by the number of MagicMed shares subject to such MagicMed stock option. F6 · price: Received in exchange for options to acquire 375,000 shares of common stock of MagicMed with an exercise price of $0.50 per share in connection with the Amalgamation. Read SEC document |
| September 16, 2021 Filed Oct 15, 2021 23:12 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantCommon Stock | 531,602 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-21-025625 · ownership.xml · nonDerivative · entry 2 Facchini Peter J. · CIK 0001883966 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 531,602 F1 · price: Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the "Amalgamation Agreement"), by and among Enveric Biosciences, Inc. (the "Company"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), ("HoldCo"), 1306436 B.C. Ltd., ("Purchaser"), and MagicMed Industries Inc. ("MagicMed"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.2658 (the "Exchange Ratio") multiplied by the number of MagicMed shares held by each such MagicMed shareholder. F3 · price: Received in exchange for 2,000,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement. F4 · ownership.nature: Held indirectly through the Facchini 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Facchini and his family. Read SEC document |
| September 16, 2021 Filed Oct 15, 2021 23:12 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantCommon Stock | 85,056 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-21-025625 · ownership.xml · nonDerivative · entry 1 Facchini Peter J. · CIK 0001883966 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,056 F1 · price: Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the "Amalgamation Agreement"), by and among Enveric Biosciences, Inc. (the "Company"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), ("HoldCo"), 1306436 B.C. Ltd., ("Purchaser"), and MagicMed Industries Inc. ("MagicMed"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.2658 (the "Exchange Ratio") multiplied by the number of MagicMed shares held by each such MagicMed shareholder. F2 · price: Received in exchange for 320,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.